Article | August 30, 2022

What CDMOs Should Know About Container Closure Integrity

By Tyler Harris, Application Engineer, PTI Inspection Systems

Manufacturing equipment in pharmaceutical factory GettyImages-1321343457

A critical component essential to maintaining the quality of a drug is its packaging, which safeguards the product as well as the company’s promise to patient safety throughout the life cycle until delivery. According to USP <1207>, container closure integrity testing (CCIT) offers assurance of a package’s ability to prevent loss and maintain product sterility. However, a lack of understanding about CCIT could put a CDMO at a disadvantage among those competitors adopting advanced CCIT solutions that accommodate the individual needs of their customers’ products. Download this full article to learn what CDMOs should know about CCIT as well as the solutions available to not only protect customers’ products but also help instill the culture of quality that is driving accountability and resiliency across today’s industry.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online

PTI Packaging and Inspection Systems